Engineered CHO Cell Lines for Enhanced Recombinant Protein Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant protein therapeutic products in CHO cell cultures face limitations in efficiency, with challenges in extending cell culture longevity, accelerating growth rates, and maximizing viable cell density, despite advancements in cell line engineering and process optimization.
Innovation Solution
Genetically engineered cells with targeted modulation of specific genes in catabolic, anabolic, secretion, protein folding, growth factor, cytotoxicity, anti-apoptosis, and gene expression pathways to enhance protein production, including up- or down-regulation of genes such as Hk1, Akt, XIAP, and others, combined with metabolic analysis and media supplementation to optimize energy production and protein folding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If cell line engineering focuses on extending longevity and accelerating growth rate, then protein production efficiency improves, but energy production and nutrient metabolism become insufficient to support sustained high-level protein production
Solution Approach 1:
The patent segments the metabolic pathways into distinct catabolic and anabolic components, independently engineering each to optimize both energy production and protein synthesis. By separating these functions into distinct genetic modules, the cell can simultaneously enhance energy generation capacity and protein production without compromising either aspect.
Solution Approach 2:
The patent applies parameter changes by systematically modulating the expression levels of key metabolic genes (HK1, PFK1, PKM, IDH3G for catabolism; and various anabolic genes for protein synthesis). By adjusting these genetic parameters, the cell achieves optimized energy production that supports sustained high-level protein production.
2Speed
If catabolic pathway genes are upregulated to enhance energy production, then growth rate increases, but protein folding and secretion may be compromised without coordinated anabolic enhancement
Solution Approach 1:
The patent merges the engineering of catabolic and anabolic pathways into a unified cell line modification strategy. By combining upregulation of catabolic genes (HK1, PFK1, PKM, IDH3G) with coordinated upregulation of anabolic genes involved in protein folding and secretion, the system achieves both enhanced growth rate and maintained protein quality.
Solution Approach 2:
The patent employs copying by introducing multiple copies of key metabolic genes into the cell genome. This gene amplification strategy ensures sufficient enzyme protein production to support both enhanced energy metabolism and coordinated anabolic processes, preventing bottlenecks in either pathway.
3Quantity of substance
If multiple genes are introduced to enhance protein expression, then titer increases, but cell culture longevity and viability may be reduced due to metabolic burden
Solution Approach 1:
The patent uses parameter changes by carefully controlling the expression levels of introduced genes through promoter selection and regulatory element optimization. By tuning these parameters, the cell achieves high protein titer while minimizing metabolic burden that would otherwise reduce cell culture longevity.
Data Source
AI summary
The present disclosure relates to engineered cells that include genetic alterations leading to up- or down-regulation of certain genes in the cells for improved production of a recombinant protein. Also provided are methods of preparing and using such cells.